Development of primary central nervous system post-transplant lymphoproliferative disorder immediately after cytomegalovirus viremia in an MDS patient who received cord blood transplantation

　Epstein–Barr virus (EBV) plays a central role in the pathogenesis of posttransplant lymphoproliferative disorder (PTLD), and EBV reactivation after allogenic hematopoietic stem cell transplantation (allo-HSCT) is highly correlated with cytomegalovirus (CMV) reactivation, which might be a risk factor for PTLD. We encountered a myelodysplastic syndrome patient with PTLD in the central nervous system who experienced sequential CMV and EBV reactivation immediately after allo-HSCT. Previous studies have suggested relationships between CMV and EBV reactivation and between CMV reactivation and PTLD. Our case suggests the importance of CMV monitoring in patients after allo-HSCT to preventPTLD

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1

Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with dasatinib alone; additionally, we previously reported another case of long-term remission maintained with imatinib monotherapy. These results suggested that a treatment with a novel and significantly potent TKI may be effective in AML with BCR-ABL1 patients with low tumor burden and without additional chromosome aberrations and ABL kinase domain mutations